Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC

This multi-center randomized controlled phase II trial was carried out in several hospitals in China to evaluate the efficacy and safety of radiotherapy or radical prostatectomy combined with intense androgen deprivation therapy for newly diagnosed metastatic prostate cancer.

Trial Details

NCT ID
NCT06992232
Phase
PHASE2
Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Intense androgen deprivation therapy
  • Radiation Therapy
  • radical prostatectomy
Locations (sample)
  • Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

  • Histologically or cytologically confirmed prostate adenocarcinoma, with distant metastasis diagnosed by novel imaging modalities (PSMA PET/CT or PS…
  • The primary lesion is deemed resectable, or can achieve a resectable state following IADT.
  • Non-castration range (≥50 ng/dl), or the duration of testosterone levels in the castration range is no more than 3 months.
  • Eastern Cooperative Oncology Group (ECOG) physical condition score ≤ 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →